Preventive treatments
Protocol amendment:
The COVID-NMA stopped including preventive treatment trials. The analysis presented in this page includes preventive trials identified and included up to Oct 22, 2021.
Please choose a Treatment Comparison:
- Bamlanivimab (LY-CoV555) vs Placebo (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Bromhexine hydrochloride vs Standard care (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Casirivimab+Imdevimab (REGN-COV2) vs Placebo (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Hydroxychloroquine vs Standard care/Placebo (10 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Hydroxychloroquine vs Vitamin C (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Ivermectin vs Standard care (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Ivermectin vs Vitamin C (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Ivermectin+Iota Carrageenan vs Standard care (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Lopinavir + Ritonavir vs Standard care (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Povidone iodine vs Vitamin C (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Social distancing at sports training vs No access to sports training facilities (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Surgical mask vs Standard care (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- video training in PPE donning and doffing vs live instructor-led training in PPE donning and doffing (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
- Zinc oxide+Vitamin C vs Vitamin C (1 RCTs) - This comparison will not be updated. Last search date Oct 22, 2021
Description of primary studies
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04329923 Abella BS, JAMA Intern Med, 2020 Full text Commentary Commentary |
Private | Hydroxychloroquine | Placebo | RCT | Healthcare worker with ≥20 hours per week of clinical work scheduled in the coming 2 months during the COVID-19 pandemic. | N=132 |
Some concerns Details |
|
| NCT04328961 Barnabas R, Ann Intern Med, 2020 Full text Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Household contacts of an index case (diagnosed with SARS-CoV2 infection with the past 14 days) or health care workers who cared for an index case without appropriate personal protective equipment recently exposed (<96 hours) | N=829 |
Some concerns Details |
|
| NCT04308668 Boulware DR, N Engl J Med, 2020 Full text Commentary Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Persons who had household or occupational exposure to a person with confirmed Covid-19 at a distance of less than | N=821 |
Some concerns Details |
|
| NCT04406909 Bretthauer M, medRxiv, 2020 Full text Commentary |
Public | Social distancing at sports training facilities | No access to sports training facilities | RCT | General public not at high risk for Covid-19 with membership to local sports training facilities. | N=3764 |
High Details |
|
| NCT04337541 Bundgaard H Full text Commentary Commentary Commentary Commentary |
Public | Surgical mask | Standard care | RCT | Workers with exposure to other people for more than 3 hours per day who do not normally wear a face mask, and who are community-dwelling adults aged 18 years or older without current or prior symptoms or diagnosis of COVID-19 | N=6024 |
Some concerns Details |
|
| NCT04701710 Chahla RE Full text Commentary Commentary |
No specific funding | Ivermectin+Iota-Carrageenan | Standard care | RCT | NR | N=234 |
Some concerns Details |
|
| N/A Christensen L, Disaster Med Public Health Prep, 2020 Full text |
Not reported/unclear | video training in PPE donning and doffing | live instructor-led training in PPE donning and doffing | RCT | Healthcare professionals receiving PPE use training in Denmark. | N=21 | N/A | |
| NCT04497987 Cohen M, BLAZE-2, 2021 Full text Commentary Commentary |
Mixed | Bamlanivimab (LY-CoV555) | Placebo | RCT | NR | N=1175 |
Details |
|
| NCT04331834 Grau-Pujol B, Research Square, 2020 Full text Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Healthcare workers with ongoing exposure to persons with Covid-19 | N=269 |
High Details |
|
| NCT04364022; SNCTP 000003732 Labhardt N, COPEP, 2021 Full text Commentary |
Public/nonprofit | Lopinavir-Ritonavir | Standard care | RCT | Asymptomatic individuals ?16 years close contacts with a person with a confirmed SARS-CoV-2 infection | N=321 |
Some concerns Details |
|
| NCT04405999 Mikhaylov E Full text Commentary Commentary |
Public/nonprofit | Bromhexine hydrochloride | Standard care | RCT | Medical staff managing patients with suspected and confirmed COVID-19 | N=50 |
Some concerns Details |
|
| NCT04304053 Mitja O, N Engl J Med, 2020 Full text Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Adults with a recent history of close contact exposure to a PCR confirmed Covid-19 case and absence of Covid-19-like symptoms, as either a healthcare worker,a household contact, a nursing home worker or a nursing home resident. | N=2525 |
Some concerns Details |
|
| NCT04334148 Naggie S Full text Commentary Commentary |
Public/nonprofit | Hydroxychloroquine | Placebo | RCT | NR | N=1360 |
Some concerns Details |
|
| NCT04452318 O'Brien M, N Engl J Med, 2021 Full text Full text Commentary Commentary |
Mixed | Casirivimab+Imdevimab (REGN-COV2) | Placebo | RCT | Asymptomatic, healthy adult (>18 years of age) and adolescent (>12 to <18 years) household contacts of the first known household member with SARS-CoV-2 infection (defined as the index case) who were RT-qPCR–negative/seronegative and lived with the index case for at least 28 days. | N=2475 |
Low Details |
|
| NCT04328467 Rajasingham R, medRxiv, 2020 Full text Commentary and Commentary |
Mixed | Hydroxychloroquine 400mg QW | Placebo | RCT | Healthcare workers with ongoing exposure to persons with Covid-19 | N=1483 |
Some concerns Details |
|
| Hydroxychloroquine 400mg BW | Placebo | |||||||
| Hydroxychloroquine 400mg QW | Hydroxychloroquine 400mg BW | |||||||
| NCT04318015 Rojas-Serrano J Full text Commentary Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | NR | N=130 |
Some concerns Details |
|
| NCT04446104 Seet R Full text Commentary |
Mixed | Hydroxychloroquine | Vitamin C | RCT | NR | N=3358 |
Some concerns Details |
|
| Ivermectin | Vitamin C | |||||||
| Povidone iodine | Vitamin C | |||||||
| Zinc oxide+Vitamin C | Vitamin C | |||||||
| NCT04422561 Shouman W, J Clin Diagnostic Res, 2021 Full text Commentary |
No specific funding | Ivermectin | Standard care | RCT | Asymptomatic household family members in close contact with cases of COVID-19 diagnosed and confirmed by Reverse Transcription- Polymerase Chain Reaction | N=340 |
High Details |
|
| NCT04359537 Syed F, CHEER, 2021 Full text Commentary Commentary |
Private | Hydroxychloroquine 400 mg* qweek | Placebo | RCT | NR | N=200 |
Some concerns Details |
|
| Hydroxychloroquine 400 mg q3week | Placebo | |||||||
| Hydroxychloroquine 200 mg q3week | Placebo | |||||||